Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743952 | 0.88 | OPRL1 (0.56) | OPRL1ALDH1A1 | |
| SCHEMBL13480021 | 0.85 | OPRL1 (1.00) | OPRL1ALDH1A1L3MBTL1OPRM1OPRK1 | |
| SCHEMBL3729432 | 0.82 | OPRL1 (0.71) | OPRL1ALDH1A1L3MBTL1OPRM1OPRK1 | |
| SCHEMBL3730224 | 0.80 | OPRL1 (0.64) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13480084 | 0.79 | OPRL1 (0.62) | OPRL1ALDH1A1OPRM1OPRK1 | |
| SCHEMBL13041512 | 0.78 | OPRL1 (0.67) | OPRL1OPRM1OPRK1 | |
| SCHEMBL3178584 | 0.77 | OPRL1 (0.66) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13480091 | 0.77 | OPRL1 (0.65) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13480113 | 0.76 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13480068 | 0.76 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | OPRL1 233/4885ALDH1A1 2486/4885L3MBTL1 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.